Endocrine-Conditions

Is This MannKind's Greatest Risk?

Not long ago, some predicted that MannKind faced the serious risk of striking out on winning approval for Afrezza. Instead, those...

Down 7%: Clovis' ASCO News

Clovis Oncology's  lung cancer drug CO-1686 was in the spotlight at ASCO today, and, while the drug seemed to be potentially more...

The Biggest Biotech Wins of the Week

While most industry analysts had their hands full with recently released ASCO abstracts, a handful of clinical wins flew largely under the...

MannKind's Next Catalyst

It's been a long wait, but MannKind is finally on the home stretch toward gaining Food and Drug Administration approval for its inhaled...